Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock.

A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald began coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Trading Down 0.5 %

NASDAQ:ATYR opened at $3.97 on Friday. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.66. The firm has a market capitalization of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The business has a 50 day simple moving average of $3.65 and a 200 day simple moving average of $3.08.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Equities research analysts predict that Atyr PHARMA will post -0.91 EPS for the current year.

Institutional Trading of Atyr PHARMA

A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. JPMorgan Chase & Co. raised its stake in shares of Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after buying an additional 10,754 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $170,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $36,000. D.A. Davidson & CO. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth $144,000. Institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.